SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
(State or Other Jurisdiction
(Commission File Number)
(Address of principal executive office) (zip code)
Registrant's telephone number, including area code: (
(Former name or former address, if changed since last report)
Title of each class
Name of each exchange
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Section 5 Corporate Governance and Management.
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain officers: Compensatory Arrangements of Certain Officers.
Ronald D. McCall, a director of CryoLife, Inc. (the “Company”) since 1984, and Harvey Morgan, a director of the Company since 2008, each notified the Company on March 21, 2021, of his decision not to stand for re-election as a director at the Company’s 2022 Annual Meeting of Stockholders, if he is re-elected as a director at the 2021 Annual Meeting of Stockholders. Mr. McCall’s and Mr. Morgan’s decisions not to stand for re-election were not due to any disagreement with management on any matter relating to the Company’s operations, policies, or practices.
Pursuant to the requirements of the Securities Exchange Act of 1934, CryoLife, Inc. has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: March 23, 2021
/s/ D. Ashley Lee
D. Ashley Lee
Executive Vice President, Chief
Operating Officer and Chief